Effect of progesterone on preventing preterm birth and adverse perinatal outcomes in women in the risk group: A prospective clinical trial

Pareshan Faris  Asaad; Ariana Khalis  Jawad

doi:10.56056/amj.2023.199

Authors

Pareshan Faris Asaad MBChB, KHCMS trainee in Obstetrics and Gynecology, Maternity teaching hospital, Erbil, Kurdistan –Iraq
Ariana Khalis Jawad CABAG, FICMS, Professor in Obstetrics and Gynecology. Kurdistan Higher Council of Medical Specialties. Erbil, Kurdistan -Iraq

DOI:

https://doi.org/10.56056/amj.2023.199

Keywords:

Clinical study, Neonatal outcomes, Preterm birth, Progesterone

Abstract

Background and Objective: Preterm labor is a significant reason for perinatal mortality and morbidity. This study was conducted to determine the effect of two regimens of progesterone to avoid preterm labor and the adverse perinatal outcomes in the two groups.

Methods: A prospective clinical trial was performed in Maternity Teaching Hospital and Hawler Private Hospital in Erbil city, Kurdistan region, Iraq over a one-year period from 1 May 2019 until 1 May 2020. The study sample was 200 pregnant women with a short cervix and a risk of preterm birth; the sample was divided into two groups. Group I of 100 pregnant women received 400 mg progesterone vaginally once daily, and group II of 100 pregnant women received it twice daily, started from 16 weeks of gestation up to the time of delivery in both groups.

Results: The rate of term pregnancy (? 37 weeks) was 87% among women in group II and 55% in women in group I. Accordingly, the rate of neonatal intensive care admission was significantly higher in group I than in group II (30% and 11%, respectively). The rate of respiratory distress syndrome was also significantly higher in group I (31%) than in group II (7%).

Conclusion: The administration of progesterone 400 mg vaginally twice a day appears to be more effective than progesterone 400 mg vaginally once a day in preventing preterm birth and reducing the risk of adverse neonatal complications.

Downloads

Download data is not yet available.

References

(Vogel JP, et al. The global epidemiology of preterm birth. Best Pract Res Clin Obstet Gynaecol 2018; 52:3–12. e1-236.e7.

Souza RT, Costa ML, Mayrink J. et al. Perinatal outcomes from preterm and early term births in a multicenter cohort of low-risk nulliparous women. Sci Rep. 2020: 10, 8508. https://doi.org/10.1038/s41598-020-65022-z.

Lincetto O, Banerjee A. World Prematurity Day: improving survival and quality of life for millions of babies born preterm around the world. Am J Physiol Lung Cell Mol Physiol. 2020; 1;319(5): L871-L874. doi:10.1152/ajplung.00479.2020.

Mwaniki MK, Atieno M, Lawn JE, Newton CR. Long-term neurodevelopmental outcomes after intrauterine and neonatal insults: A systematic review. Lancet. 2012;379(9814):445-52.

Li S, Zhang M, Tian H, Liu Z, Yin X, Xi B. Preterm birth and risk of type 1 and type 2 diabetes: systematic review and meta-analysis: Preterm birth and diabetes. Obes Rev. 2014;15(10):804-11.

Harrison M.S, Goldenberg R.L. Global burden of prematurity. Semin Fetal Neonatal Med. 2016; 21(2):74-9.

Newnham JP, Dickinson JE, Hart RJ, Pennell CE, Arrese CA, Keelan JA. Strategies to prevent preterm birth. Front Immunol. 2014 ;5 :584.

Conde-Agudelo A, Romero R, Da Fonseca E, et al. previous spontaneous preterm birth, and a short cervix: updated indirect comparison meta-analysis. Am J Obstet Gynecol. 2018 ; 218 :161-80. doi: 10.1016/j.ajog.2018.03.028.

Norman JE, Marlow N, Messow CM, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016; 387(10033):2106-16.

Vedel C, Larsen H, Holmskov A, et al. Long-term effects of prenatal progesterone exposure: neurophysiological development and hospital admissions in twins up at 8 years of age. Ultrasound Obstet Gynecol. 2016; 48(3):382-9.

Luo G, Abrahams VM, Tadesse S, et al. Progesterone inhibits basal and TNF-alpha-induced apoptosis in fetal membranes: a novel mechanism to explain progesterone-mediated prevention of preterm birth. Reprod Sci 2010; 17(6):532-9.

Boelig RC, et al. Pharmacokinetics of vaginal progesterone in pregnancy. Am J Obstet Gynecol. 2019;221(3): 263.e1-263.e7.

Bernal AL. Overview. Preterm labour: mechanisms and management. BMC Pregnancy and Childbirth 2007; 7 (1): S2.

Ibrahim M, Ramy AR, Younis MA. Progesterone supplementation for prevention of preterm labor: A randomized controlled trial. Middle East Fertil Soc J. 2010; 15 (1): 39-41.

Khazaali EA. Vaginal progesterone pessary for preterm labor prevention in women with a short cervix early in the second trimester. Iraqi JMS 2018; 16(2): 133-43.

Mesiano S, Chan EC, Fitter JT. Progesterone withdrawal and estrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium. J Clin Endocrinol Metab 2002 ; 87(6) :2924-30.

Jeschke U, Mylonas I, Richter DU, et al. Regulation of progesterone production in human term trophoblasts in vitro by CRH, ACTH and cortisol (prednisolone). Arch Gynecol Obstet 2005; 272(1):7-12.

Norwitz ER, Wilson T. Secretory component: a potential regulator of endometrial-decidual prostaglandin production in early human pregnancy. Am J Obstet Gynecol 2000; 183(1):108-17.

Luo G, Abrahams VM, Tadesse S, et al. Progesterone inhibits basal and TNF-alpha-induced apoptosis in fetal membranes: a novel mechanism to explain progesterone-mediated prevention of preterm birth. Reprod Sci. 2010;17(6):532-9.

Azargoon A, Ghorbani R, Aslebahar F. Vaginal progesterone on the prevention of preterm birth and neonatal complications in high-risk women: A randomized placebo-controlled double-blind study. Int J Reprod Biomed 2016; 14(5):309-16.

Norman JE. Progesterone and preterm birth. Int J Gynecol Obstet 2020; 150(1): 24–30.

Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labor: A randomized controlled trial. Aust NZ J Obstet Gynecol 2008:48(1):58-63.

Dodd JM, Crowther CA, McPhee AJ, Flenady V, Robinson JS. Progesterone after previous preterm birth for prevention of neonatal respiratory distress syndrome (PROGRESS): a randomised controlled trial. BMC Pregnancy Childbirth 2009; 9(1):6.

Crowther CA, Ashwood P, McPhee AJ, et al. Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS Study): A multicentre, randomised, placebocontrolled trial. PLoS Med 2017; 14(9): e1002390.